Adult: 60-100 mg/m2 by infusion over 1 hr once every 3 wk. In combination w/ doxorubicin or capecitabine or as adjuvant therapy w/ doxorubicin and cyclophosphamide: 75 mg/m2 once every 3 wk. In combination w/ trastuzumab: 100 mg/m2 once every 3 wk.
Intravenous Gastric adenocarcinoma, Head and neck cancer, Non-small cell lung cancer, Prostate cancer
Adult: 75 mg/m2 by infusion over 1 hr once every 3 wk. For gastric adenocarcinoma: Dose is given before cisplatin and fluorouracil. For head and neck cancer: Given before cisplatin and fluorouracil for 3 cycles followed by chemoradiotherapy or 4 wk followed by radiotherapy alone. For prostate cancer: May be given w/ oral prednisolone 5 mg bid continuously during treatment.
Breast cancer: Mild to moderate: Reduce dose from 100 mg/m2 to 75 mg/m2. Severe: Avoid use. Non-small cell lung cancer; Gastric adenocarcinoma; Head and neck cancer; Prostate cancer Severe: Avoid use.
Add 1 mL of diluent to a 20 mg vial to provide a soln containing 20 mg/0.8 mL or 4 mL of diluent to 80 mg vial to provide a soln containing 24 mg/mL of the drug. Shake well to ensure complete dissolution of the drug. The required amount of reconstituted soln should be injected into a 250-mL infusion bag or bottle containing NaCl 0.9% inj or dextrose 5% inj to produce a final soln of 0.3-0.74 mg/mL. For doses >200 mg, the vol of IV soln should be increased accordingly so that the concentration does not exceed 0.74 mg/mL.
Y-site: Amphotericin B, doxorubicin liposome, methylprednisolone Na succinate, nalbuphine.
Baseline neutrophil count of <1,500 cells/mm3. Severe hepatic impairment.
Patient w/ severe fluid retention, resp disorders, eye disorders. Renal and mild to moderate hepatic impairment. Pregnancy and lactation.
May cause symptoms of alcohol intoxication. May impair ability to drive or operate machinery.
Monitor haematologic, hepatic and renal functions; monitor for hypersensitivity reactions, neurosensory symptoms, GI toxicity, cutaneous reactions, visual impairment, fluid retention, epiphora, and canalicular stenosis; baseline cardiac assessment and cardiac function monitoring in patients given docetaxel w/ other cytotoxic drugs esp trastuzumab.
Symptoms: Bone marrow suppression, peripheral neurotoxicity and mucositis. Management: Symptomatic treatment. Admin therapeutic granulocyte-colony stimulating factor (G-CSF) as soon as possible.
CYP3A4 inducers, inhibitors, or substrates may alter docetaxel metabolism.
Description: Docetaxel promotes the assembly of microtubules from tubulin dimers, and inhibits the depolymerisation of tubulin which stabilizes microtubules in the cell. This results in inhibition of DNA, RNA, and protein synthesis. Most activity occurs during the M phase of the cell cycle. Pharmacokinetics: Distribution: Rapidly distributed to body tissues. Plasma protein binding: >95%. Metabolism: Extensively hepatic, by CYP3A4 isoenzyme. Excretion: Mainly via faeces (as metabolites); via urine (approx 6%). Terminal elimination half-life: Approx 11 hr.
Anon. Docetaxel . Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. https://online.lexi.com. Accessed 05/11/2014.Buckingham R (ed). Docetaxel. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 05/11/2014.Docetaxel Anhydrous Injection, Solution (Hospira, Inc). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/. Accessed 05/11/2014.Docetaxel: Drug Safety Communication. U.S. FDA. https://www.fda.gov/. Accessed 05/11/2014.McEvoy GK, Snow EK, Miller J et al (eds). Docetaxel. AHFS Drug Information (AHFS DI) [online]. American Society of Health-System Pharmacists (ASHP). https://www.medicinescomplete.com. Accessed 05/11/2014.Taxotere Injection Concentrate. U.S. FDA. https://www.fda.gov/. Accessed 05/11/2014.